Sun Pharma News: Key Updates and Insights

Sun Pharma has been in the news lately for its acquisition of GSK's Australian consumer healthcare business, which is valued at around $1.5 billion. This move is expected to strengthen Sun Pharma's presence in the Australian market.

The acquisition includes a range of well-known brands such as Panadol and Voltaren. Sun Pharma is also planning to expand its operations in Australia, creating new job opportunities and increasing its manufacturing capacity.

Sun Pharma's revenue has been steadily increasing over the years, with a growth rate of 10% in the last quarter. The company's focus on research and development has also led to the launch of several new products, including a generic version of the popular diabetes medication, Januvia.

Sun Pharma has also been making headlines for its commitment to sustainability, with a goal to reduce its carbon footprint by 50% by 2025. The company has already made significant strides in this area, with a 20% reduction in greenhouse gas emissions in the last year.

Here's an interesting read: Sun Communities Reit

Sun Pharma shares rose up to 3.5% on October 1, 2025, after a 7-day losing run was snapped due to the Pfizer-Trump deal.

The company may face tariff turbulence in the US, but HSBC sees limited earnings risk.

Sun Pharma's stock has been impacted by the Sensex and Nifty extending losses for 6 days, with IT, pharma, and PSU banks dragging the market down.

The smallcap index declined 1.5% on September 26, 2025, with Sun Pharma's stock likely being affected by this broader market trend.

Here are some key dates related to Sun Pharma news:

Sun Pharma has announced an earnings call for the second quarter financial results on November 5, 2025. This is an important event for investors and stakeholders to stay informed about the company's performance.

The Board of Directors meeting is also scheduled on the same day, November 5, 2025. This meeting will likely discuss various corporate matters and strategies for the company's future growth.

Sun Pharma has also released its ESG Overview for FY 2024-25, providing valuable insights into the company's environmental, social, and governance practices.

Here are the key announcements related to corporate actions:

As you follow the corporate actions of a company, you'll often come across announcements that provide valuable information about the company's financials and operations.

The latest announcement from Sun Pharmaceutical Industries Ltd states that the meeting of the Board of Directors is scheduled on 05 November 2025.

You can also expect the company to hold an earnings call for the financial results of the second quarter on 05 November 2025. This is a great opportunity to learn more about the company's performance and ask questions to the management team.

The ESG Overview for FY 2024-25 has also been announced, providing insights into the company's environmental, social, and governance practices.

Here are some key corporate actions that you might find useful to track:

If you're interested in understanding the company's financials, you can check the announcement dates for the consolidated and standalone financial results.

Moneycontrol is a great platform for investors, offering advanced AI-based features to make informed decisions. Their products are continually improved to provide the best experience for users.

You can use their SWOT analysis, investment checklist, technical ratings, and valuation analysis to determine which stock to buy and why. This helps you make a more informed investment decision.

The platform provides an analysis of stocks based on price performance, financials, the Piotroski score, and shareholding. This gives you a comprehensive view of how a company stacks up against its peers and within the sector.

To get the most out of Moneycontrol, you can read research reports, investor presentations, and listen to earnings calls. This will give you valuable insights from the best minds in the industry.

You can also track FII, DII, and MF trends, as well as promoter holdings and pledge details. This will help you understand the bigger picture and make more informed decisions.

Here are some of the key features of Moneycontrol:

Sun Pharmaceutical Industries Limited, a company featured on Moneycontrol, is a generic pharmaceutical company that develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally.

Diversity in Manufacturing is a game-changer.

Sun Pharma's Dewas plant is leading the way with a remarkable transformation in gender diversity.

Breaking the mould is exactly what they've done.

A predominantly male domain is now home to a gender diverse team that's taking charge of manufacturing blocks.

It's a testament to the power of diversity in the workplace.

The Dewas plant is showing that a diverse team can be just as effective, if not more so, than a traditional one.

In fact, a gender diverse team can bring new perspectives and ideas to the table.

This can lead to improved decision-making and a more innovative approach to problem-solving.

Sun Pharma's Dewas plant is proof that diversity and inclusion can be a key driver of success.

Suggestion: Wörwag Pharma

Sun Pharma's financial performance is a crucial aspect of its overall health. As of 9/22/2025, the company's trailing total returns include dividends or other distributions.

The benchmark for Sun Pharma's performance is the S&P BSE SENSEX (^BSESN), which provides a standard against which the company's growth can be measured.

Additional reading: Why Does the Sun Go on Shining?

Sun Pharma shares slipped 3% after Bank of America downgraded its stock to 'underperform' from 'neutral', citing risks to premium valuations and slower speciality execution.

Bank of America also cut its target price for Sun Pharma, flagging concerns over Ilumya's Medicare exposure, pricing pressures, and limited earnings visibility.

Glenmark Pharmaceuticals, Alembic Pharmaceuticals, and Sun Pharmaceutical Industries all experienced stock declines following USFDA reports of product recalls in the US market due to manufacturing issues.

The recalls included Glenmark's Carvedilol and Theophylline tablets, Alembic's Doxepin Hydrochloride capsules, and Sun Pharma's US arm's Spironolactone tablets, all classified as Class II recalls by the USFDA.

These recalls highlighted the importance of maintaining high manufacturing standards in the pharmaceutical industry.

Additional reading: Sun Weigh

The performance of a company's stock can be a great indicator of its overall financial health. As of 9/22/2025, the trailing total returns of Ns include dividends or other distributions.

Benchmarking is a useful way to compare a company's performance to its peers. The S&P BSE SENSEX (^BSESN) serves as a benchmark for Ns.

Evaluating a company's performance over time can provide valuable insights. Trailing total returns are an important metric to consider when assessing a company's financial performance.

By comparing a company's performance to a benchmark, you can get a better sense of its strengths and weaknesses. The S&P BSE SENSEX (^BSESN) is a widely recognized benchmark in the Indian stock market.

Sun Pharma's valuation metrics are quite impressive, with a market cap of 3.97 trillion dollars. This massive market value is a testament to the company's growth and success.

The company's enterprise value is also substantial, standing at 3.73 trillion dollars. This is a key metric to consider when evaluating a company's overall value.

Take a look at this: Credit Market News

Sun Pharma's trailing P/E ratio is a bit on the higher side, coming in at 38.24. This means that investors are paying a premium for the company's shares.

The company's price-to-sales ratio is 7.45, which is a bit above the industry average. This could be a red flag for some investors.

Here's a summary of Sun Pharma's valuation metrics:

Valuation Measures can be a bit overwhelming, but let's break it down. Market Cap is a whopping 3.97 trillion dollars.

To put that into perspective, Enterprise Value is almost as high, at 3.73 trillion dollars. This gives us an idea of the company's worth.

The Trailing P/E is 38.24, which can be a bit tricky to understand. Essentially, it's a ratio of the company's stock price to its earnings per share over the past year.

A Forward P/E is not available, which means we'll have to rely on other metrics for now. The Price/Sales ratio is 7.45, which is a common metric to evaluate a company's stock price relative to its revenue.

A Price/Book ratio of 5.50 is also noteworthy, as it compares the company's stock price to its book value. This can be a useful indicator of a company's financial health.

Here are some key valuation metrics to keep in mind:

Sun Pharmaceutical Industries recently made an announcement under Regulation 30 (LODR) regarding an Analyst/Investor Meet - Intimation. This indicates that the company is engaging with analysts and investors to discuss its performance and future prospects.

The US healthcare system is a significant market for Indian generic drug companies, with India being the biggest supplier of these medicines. Sun Pharmaceutical Industries is likely to benefit from this, as there is a sense of relief among Indian drug companies due to the indication that no additional or special tariff will be imposed by the US.

This tariff threat had been troubling Indian companies for the past year, and its removal is a positive development for the industry.

Sun Pharmaceutical Industries has recently received a Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018.

The company has also intimated the schedule of its Analyst/Institutional Investor Meeting, but no further details are provided in the article.

Benchmark indices Nifty and Sensex opened in the green on Monday, September 29, marking a break from a six-day losing streak.

The SEBI DP Reg. 74(5) Certificate is an important document that needs to be obtained by companies. It's a compliance certificate that Sun Pharmaceutical Industries has obtained.

Sun Pharmaceutical Industries has indeed obtained this certificate, as mentioned in the article. The certificate is under Reg. 74(5) of SEBI (DP) Regulations, 2018.

Benchmark indices Nifty and Sensex opened in the green on Monday, September 29, but the certificate is not related to stock market performance. It's a regulatory requirement that companies must fulfill.

The certificate is a proof that Sun Pharmaceutical Industries has fulfilled the regulatory requirements. This is a crucial step in maintaining the company's compliance with SEBI regulations.

Institutional investors and analysts may request to see this certificate before making investment decisions.

Indian pharma companies are a significant supplier of generic drugs to the US market.

The US healthcare system relies heavily on these generic drugs, and any increase in their cost would have disrupted the system.

NCLT (National Company Law Tribunal) has approved a Composite Scheme of Arrangement for Sun Pharmaceutical Industries.

This approval is a result of an announcement under Regulation 30 (LODR) of the company.

A tariff threat that had been troubling Indian companies for a year has seemingly been resolved, with no additional or special tariff to be imposed on generic drugs.

The resolution of this threat is a welcome relief for Indian pharma companies.

The US FDA inspection at Sun Pharma's Halol facility has been a topic of interest. Sun Pharmaceutical Industries has provided an update on the inspection.

The fear of a possible tariff hike in the pharma sector is palpable. This is because any additional duty will lead to higher medicine costs in the US, resulting in higher inflation.

President Trump has not tariffed the pharma sector so far, likely due to concerns about higher medicine costs and inflation.

Sun Pharma is a leading pharmaceutical company in India, with a global presence in over 100 countries. It was founded in 1983 by Dilip Shanghvi.

The company's market capitalization is over $20 billion, making it one of the largest pharmaceutical companies in India. Sun Pharma's revenue has grown significantly over the years, with a compound annual growth rate (CAGR) of 15%.

Sun Pharma's product portfolio includes a wide range of pharmaceuticals, including specialty products, generic drugs, and over-the-counter (OTC) products. The company has a strong presence in the domestic market, with a market share of over 10% in the Indian pharmaceutical market.

Sun Pharma's research and development (R&D) efforts have led to the development of several new products, including a new treatment for psoriasis. The company has also partnered with other pharmaceutical companies to develop new products and expand its global presence.

The Indian pharmaceutical market is expected to grow at a CAGR of 10% over the next five years, driven by increasing demand for generic drugs and specialty products. Sun Pharma is well-positioned to benefit from this growth, with a strong portfolio of products and a growing presence in the domestic market.

Sun Pharma's market share in the Indian pharmaceutical market has increased to 13.9% in 2022, up from 12.7% in 2020.

The company's revenue from the US market has seen a significant growth of 23% in 2022, reaching $1.4 billion.

Sun Pharma's partnership with Novartis has helped the company to expand its product portfolio and enter new markets.

The company's global presence spans over 100 countries, with a strong distribution network in place.

Sun Pharma's focus on research and development has led to the launch of new products, including a generic version of the popular anti-inflammatory drug, Humira.

Sun Pharma has reached a settlement with Incyte Corporation, launching Leqselvi in the U.S. for the treatment of severe alopecia areata.

The settlement and license agreement involves Sun Pharma seeking dismissal of pending litigation in the United States District Court for the District of New Jersey.

Incyte has granted Sun a limited, non-exclusive license to U.S. Patent and certain related patents for oral deuruxolitinib in non-hematology-oncology indications, including alopecia areata, in the U.S.

Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, for the settlement and license.

The launch of Leqselvi in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and healthcare providers.

Pharmazz Inc. recently secured a $25M equity investment, a significant boost to the company's growth plans.

This investment will enable Pharmazz to accelerate the development of its innovative pharmaceutical products.

Pharmazz aims to leverage this funding to expand its research and development capabilities.

The company's focus on developing novel treatments for complex diseases will likely benefit from this increased investment.

Pharmazz Inc.'s partnership with a leading healthcare investor will provide valuable strategic guidance and support.

Sun Pharma has reached a settlement with Incyte Corporation, a significant milestone in its journey.

The settlement and license agreement allows Sun Pharma to launch Leqselvi in the U.S. for the treatment of severe alopecia areata.

The agreement involves the dismissal of pending litigation in the United States District Court for the District of New Jersey.

Sun Pharma will pay Incyte an upfront amount plus ongoing royalty payments until the expiry of the patents.

The license granted by Incyte allows Sun Pharma to market Leqselvi for certain non-hematology-oncology indications, including alopecia areata, in the U.S.

Sun Pharma has announced the launch of Leqselvi 8 mg tablet in the U.S. for the treatment of severe alopecia areata.

The launch brings a new treatment option to eligible patients and healthcare providers.